TY - JOUR
T1 - Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil
AU - Ranzani, Otavio T.
AU - Hitchings, Matt D. T.
AU - de Melo, Rosana Leite
AU - de França, Giovanny V. A.
AU - Fernandes, C. ssia de F. tima R.
AU - Lind, Margaret L.
AU - Torres, Mario Sergio Scaramuzzini
AU - Tsuha, Daniel Henrique
AU - David, Leticia C. S.
AU - Said, Rodrigo F. C.
AU - Almiron, Maria
AU - de Oliveira, Roberto D.
AU - Cummings, Derek A. T.
AU - Dean, Natalie E.
AU - Andrews, Jason R.
AU - Ko, Albert I.
AU - Croda, Julio
N1 - Funding Information: We thank the Pan American Health Organization for its support. No external funding was provided for this study. OTR is funded by a Sara Borrell fellowship (CD19/00110) from the Instituto de Salud Carlos III. OTR acknowledges support from the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa 2019-2023 programme (CEX2018-000806-S) and from the Generalitat de Catalunya through the Centres de Recerca de Catalunya (CERCA) programme. DATC and MDH report a contract from Merck (to the University of Florida) for research unrelated to this manuscript. These institutions had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. Funding Information: We thank the Pan American Health Organization for its support. No external funding was provided for this study. OTR is funded by a Sara Borrell fellowship (CD19/00110) from the Instituto de Salud Carlos III. OTR acknowledges support from the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa 2019-2023 programme (CEX2018-000806-S) and from the Generalitat de Catalunya through the Centres de Recerca de Catalunya (CERCA) programme. DATC and MDH report a contract from Merck (to the University of Florida) for research unrelated to this manuscript. These institutions had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. Publisher Copyright: © 2022, The Author(s).
PY - 2022/12/1
Y1 - 2022/12/1
N2 - The effectiveness of inactivated vaccines (VE) against symptomatic and severe COVID-19 caused by omicron is unknown. We conducted a nationwide, test-negative, case-control study to estimate VE for homologous and heterologous (BNT162b2) booster doses in adults who received two doses of CoronaVac in Brazil in the Omicron context. Analyzing 1,386,544 matched-pairs, VE against symptomatic disease was 8.6% (95% CI, 5.6–11.5) and 56.8% (95% CI, 56.3–57.3) in the period 8–59 days after receiving a homologous and heterologous booster, respectively. During the same interval, VE against severe Covid-19 was 73.6% (95% CI, 63.9–80.7) and 86.0% (95% CI, 84.5–87.4) after receiving a homologous and heterologous booster, respectively. Waning against severe Covid-19 after 120 days was only observed after a homologous booster. Heterologous booster might be preferable to individuals with completed primary series inactivated vaccine.
AB - The effectiveness of inactivated vaccines (VE) against symptomatic and severe COVID-19 caused by omicron is unknown. We conducted a nationwide, test-negative, case-control study to estimate VE for homologous and heterologous (BNT162b2) booster doses in adults who received two doses of CoronaVac in Brazil in the Omicron context. Analyzing 1,386,544 matched-pairs, VE against symptomatic disease was 8.6% (95% CI, 5.6–11.5) and 56.8% (95% CI, 56.3–57.3) in the period 8–59 days after receiving a homologous and heterologous booster, respectively. During the same interval, VE against severe Covid-19 was 73.6% (95% CI, 63.9–80.7) and 86.0% (95% CI, 84.5–87.4) after receiving a homologous and heterologous booster, respectively. Waning against severe Covid-19 after 120 days was only observed after a homologous booster. Heterologous booster might be preferable to individuals with completed primary series inactivated vaccine.
UR - http://www.scopus.com/inward/record.url?scp=85139330546&partnerID=8YFLogxK
U2 - https://doi.org/10.1038/s41467-022-33169-0
DO - https://doi.org/10.1038/s41467-022-33169-0
M3 - Article
C2 - 36202800
SN - 2041-1723
VL - 13
JO - Nature communications
JF - Nature communications
IS - 1
M1 - 5536
ER -